The rates of multidrug-resistant, extensively drug-resistant and pandrug-resistant isolates amongst non-fermenting Gram-negative bacilli, particularly Pseudomonas aeruginosa, have risen worldwide. The clinical consequence of resistance and the impact of adverse treatment on the outcome of patients with P. aeruginosa bacteraemia remain unclear. To better understand the predictors of mortality, the clinical consequence of resistance and the impact of inappropriate therapy on patient outcomes, we analysed the first episode of P. aeruginosa bacteraemia in patients from a Brazilian tertiary-care hospital during the period from May 2009 to August 2011. Antimicrobial susceptibility testing was conducted; phenotypic detection of metallo-b-lactamase (MBL) and PCR of MBL genes were performed on carbapenem-resistant strains. Amongst the 120 P. aeruginosa isolates, 45.8 % were resistant to carbapenem and 36 strains were tested for MBL detection. A total of 30 % were phenotypically positive and, of these, 77.8 % expressed an MBL gene, bla SPM-1 (57 %) and bla VIM -type (43 %). The resistance rates to ceftazidime, cefepime, piperacillin/tazobactam, carbapenem, fluoroquinolone and aminoglycoside were 55, 42.5, 35, 45.8, 44 and 44 %, respectively. Previous antibiotic use, length of a hospital stay ¢30 days prior to P. aeruginosa, haemodialysis, tracheostomy, pulmonary source of bacteraemia and Intensive Care Unit admission were common independent risk factors for antimicrobial resistance. Cefepime resistance, multidrug resistance and extensive drug resistance were independently associated with inappropriate therapy, which was an important predictor of mortality, being synergistic with the severity of the underlying disease.
INTRODUCTION
Pseudomonas aeruginosa is a ubiquitous environmental bacterium with minimal requirements for survival and a remarkable ability to adapt to a variety of environmental challenges (Blanc et al., 2007; Singh et al., 2010) . This pathogenic plasticity is attributed to the massive genome associated with flexible metabolism and the low permeability of the outer membrane, making this pathogen resistant to a large range of harmful agents, including antibiotics (Caulcott et al., 1984; Mathee & Tam, 2008) . The resistance to antimicrobial drugs is becoming an increasingly important health and economic problem, and P. aeruginosa, one of the main micro-organisms of nosocomial infections, is known for its resistance to a range of antimicrobial agents (Hirsch & Tam, 2010; Morales et al., 2012) .
The impact of antimicrobial resistance on clinical and economic outcomes is the subject of ongoing investigation (Cosgrove, 2006) , but many studies have shown its negative impact on effective antimicrobial therapy. Inappropriate empirical therapy has been associated with increased mortality in resistant P. aeruginosa infections, and delays in starting appropriate therapy may contribute to increased length of hospital stay and persistence of infection. In addition, worse clinical outcomes may be associated with resistant infections owing to antimicrobial options of limited efficacy (Hirsch & Tam, 2010; Kang et al., 2003 Kang et al., , 2005 Lodise et al., 2007) . P. aeruginosa resistance to antipseudomonal drugs has increased in several regions of the world (Andrade et al., 2003; Kiffer et al., 2005; Sader et al., 2001; Souli et al., 2008) and the Centers for Disease Control and Prevention (CDC), with the aim of enhancing the comparability of data and of promoting better comprehension of the problem of highly drug-resistant bacteria, recently created standardized international definitions for multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria. MDR was defined as non-susceptibility to at least one agent in three or more antimicrobial categories, XDR was defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories, and PDR was defined as non-susceptibility to all agents in all antimicrobial categories (Magiorakos et al., 2012) .
Carbapenems have been considered first-line agents for the treatment of P. aeruginosa infections, mainly in severe cases; however the resistance of P. aeruginosa to these drugs has reached .60 % in some Brazilian hospitals (Baumgart et al., 2010; Kiffer et al., 2005) . Previous studies of clinical P. aeruginosa isolates have reported that resistance to carbapenems resulted from the complex interaction of several mechanisms, including the production of carbapenemase activity, usually a metallo-b-lactamase (MBL), the loss of the OprD porin and the overexpression of efflux systems (El Amin et al., 2005; Xavier et al., 2010) . MBL production was seen in up to 30 % of in patients in previous studies of Brazilian hospitals, which have shown SPM-1 as the most prevalent enzyme (Scheffer et al., 2010; Strateva & Yordanov, 2009; Wirth et al., 2009) .
Only a few studies have examined the clinical consequences of antibiotic resistance and the impact of inappropriate antimicrobial therapy on the outcomes of patients with P. aeruginosa bacteraemia. Thus, this study was performed to evaluate these factors, and to identify the predictors of mortality in patients with MDR, XDR and PDR P. aeruginosa bacteraemia. In addition, we also detected the risk factors associated with different antibiotic-resistant and MBLproducing P. aeruginosa that showed carbapenem resistance.
METHODS
Patients and setting. The database at our clinical microbiology laboratory was reviewed to identify patients with P. aeruginosa bacteraemia from May 2009 to August 2011 at Uberlandia University Hospital (Brazil), a 530-bed tertiary-care university hospital. Only the first episode was analysed for those patients with more than one episode of bacteraemia.
Study design and data collection. A retrospective study was employed to identify the predictors of mortality, and to evaluate the clinical consequence of resistance and the impact of inappropriate therapy on outcomes of patients with P. aeruginosa bacteraemia.
The main outcome was in-hospital mortality and the measure used was a 30 day mortality rate. We also assessed secondary outcomes, including the duration of hospital stay, admission to the Intensive Care Unit (ICU) and use of invasive procedures at collection of P. aeruginosa blood culture. Data from patients with antimicrobialresistant P. aeruginosa bacteraemia were compared with those from patients with susceptible bacteraemia in an effort to determine factors associated with resistance. For each study patient, the following characteristics were recovered in clinical records: age, gender, length of total hospital stay, length of hospital stay before P. aeruginosa bacteraemia, admission to ICU, surgery, invasive procedures (e.g. mechanical ventilation, central venous line, urinary catheter, tracheostomy, haemodialysis, catheter for enteral or gastric nutrition) and surgical drain during the current hospitalization. The medical histories of the patient's underlying conditions, such as diabetes mellitus, chronic renal failure, heart failure, AIDS and cancer, were determined. We also assessed the sources of bacteraemia, previous antibiotic use during current hospitalization and cases of inadequate antimicrobial treatment.
Clinical microbiological and molecular testing. Cultures were processed using BACT/Alert (bioMérieux). Microbial identification and antimicrobial susceptibility testing were performed on the VITEK-2 automated system (bioMérieux) for the following antimicrobials: ceftazidime, cefepime, piperacillin/tazobactam, carbapenem (imipenem and/or meropenem), fluoroquinolone (ciprofloxacin and/or levofloxacin), aminoglycosides (gentamicin and/or amikacin), aztreonam and polymyxin B. P. aeruginosa strains that showed reduced susceptibility were included in the resistant group. Qualitycontrol protocols were used according to the standards of the Clinical and Laboratory Standard Institute (CLSI, 2009 (CLSI, , 2010 (CLSI, , 2011 . The carbapenem-resistant P. aeruginosa isolates were phenotypically screened for MBL production using double-disc synergy tests, as previously described (Arakawa et al., 2000) . In addition, to assess the presence of MBL genes in P. aeruginosa strains, a multiplex PCR was performed, as described previously (Woodford, 2010) . The cycling conditions were: 94 uC for 5 min, followed by 30 denaturation cycles at 94 uC for 30 s, annealing at 53 uC for 45 s and extension at 72 uC for 30 s, followed by final extension at 72 uC at 10 min, all in a MasterCycler personal (Eppendorf).
Definitions. According to the CDC, bacteraemia is defined as the presence of viable micro-organisms in the bloodstream documented by a positive blood culture result. Bacteraemia was considered to be nosocomial if the infection occurred .48 h after admission and no clinical evidence of infection on admission existed (Horan et al., 2008) . Bacteraemia was classified as primary when the patient had a recognized pathogen cultured from one or more blood cultures and the organism cultured from blood was not related to an infection at another site. Catheter-related bacteraemia was defined as when the patient had an intravascular device and one or more positive blood culture results obtained from the peripheral vein, and no apparent source for infection except the catheter. Bacteraemia was considered secondary when the patient had a recognized pathogen cultured from one or more blood cultures and the organism cultured from blood was related to an infection at another site (Horan et al., 2008) . Outcomes were classified as either death or survival, but no attempt was made to determine if death was attributable directly to P. aeruginosa bacteraemia. For the comparison of outcomes, survival status was evaluated at 30 days after the onset of bacteraemia (Lodise et al., 2007) . The Average Severity of Illness Score (ASIS) was also recorded for each patient using the CDC National Nosocomial Infections Surveillance System criteria (Emori et al., 1991; Rosenthal et al., 2006) . The empirical antimicrobial therapy was considered to be 'appropriate' if the initial antibiotics, which were administered within 24 h after the acquisition of a blood culture sample, included at least one antibiotic that was active in vitro (Gilbert et al., 2007) . We considered patients to have had prior antibiotic therapy if they received an antimicrobial agent for at least 2 days within 30 days preceding the onset of P. aeruginosa bacteraemia.
Statistical analysis. Student's t-test was used to compare continuous variables and x 2 or Fisher's exact test was used to compare categorical variables. To determine independent risk factors for 30 day mortality and resistance, a multiple logistic regression model was used to control for the effects of confounding variables. Variables with P¡0.05 in the univariate analysis were candidates for multivariate analysis. A survival curve was constructed using the Kaplan-Meier method, and the logrank test was used for comparisons between patients with inappropriate and adequate therapy. All P values were two-tailed and P¡0.05 was considered to be statistically significant.
Ethical approval. The research Ethics Committee of the Federal University Uberlandia evaluated and approved our study design.
RESULTS

Study population and mortality predictors
From 1 May 2009 to 31 August 2011, a total of 120 nonrepetitive patients with P. aeruginosa bacteraemia at the university hospital were included in the study. The detailed information on factors associated with death, and the relevant demographic and clinical characteristics of the study population, are summarized in Results of a multivariate analysis for an association between cohort risk factors and hospital mortality showed that the predictors that were independently associated with death were patients with severe underlying disease, such as cancer and/or AIDS, as well as patients who received inadequate antimicrobial therapy. The median length of a hospital stay after admission was 32 days for survivors and 79 days for patients who died. The Kaplan-Meier cumulative survival estimates (Fig. 1) for patients with inappropriate versus appropriate therapy showed that the group that received inappropriate therapy had a lower probability of survival than the group that received appropriate therapy (P50.001). The 30 day mortality rate of the first group was 48.0 %, whereas that of the second group was 14.3 %. The severity of the patients was accessed through ASIS scores (Table 1) , and no significant difference was found between survivors and patients who died.
Risk factors associated with antimicrobial resistance and treatment outcome
Antimicrobial susceptibility testing results were analysed, and 58 strains (48.3 %) behaved as MDR isolates, 31 (25.8 %) behaved as XDR isolates, none behaved as PDR isolates and 31 (25.8 %) were other profiles. The resistance rates to ceftazidime, cefepime, piperacillin/tazobactam, carbapenem, fluoroquinolones and aminoglycosides were 55 (66/120), 42.5 (51/120), 35.8 (43/120), 45.8 (55/120), 45 (54/120) and 45 % (54/120), respectively. The risk factors associated with resistance to each class of antimicrobials were evaluated and the independent variables associated with the respective resistances are shown in Table 2 . The common risk factors for antimicrobial resistance were previous antibiotic use, mainly carbapenems and fluoroquinolones, haemodialysis, tracheostomy, hospitalization up to 30 days before P. aeruginosa and pulmonary source of bacteraemia.
The antibiotic therapy was evaluated and patients with bacteraemia stemming from resistant P. aeruginosa had higher inappropriate therapy rates than did those patients with susceptible bacteraemia, particularly to the cefepimeresistant (P50.02), MDR (P50.009) and XDR (P50.03) groups. Overall, when the clinical outcome was assessed, the 30 day mortality rate and time of hospital stay were higher for the resistant groups when compared with the susceptible groups (Table 3) .
MBL production
MBL production was analysed for 36 carbapenem-resistant P. aeruginosa isolates. Nine (25.0 %) isolates were phenotypically Resistant Pseudomonas aeruginosa bacteraemia positive and seven (19.4 %) presented an amplicon consistent with MBL genes, being bla SPM-1 in 57 % (4/7) and bla VIM -type in 43 % (3/7). Based on the antibiotic susceptibility testing, six antibiotypes (R1-R6) were identified amongst isolates that were phenotypically positive for MBL production. Two isolates were assigned antibiotype R1 and were XDR P. aeruginosa (resistant to all antibiotics tested, with the exception of polymyxin B). The other antibiotypes (R2-R6) fitted the MDR profile (Table 4 ).
DISCUSSION
Antimicrobial resistance is a worldwide problem with severe implications in developing countries due to the rapid emergence and spread of antimicrobial-resistant non-fermentative Gram-negative bacilli, especially P. aeruginosa isolates, thus posing a considerable threat to public health (Baumgart et al., 2010; Hirsch & Tam, 2010; Kiffer et al., 2005; Morales et al., 2012; Scheffer et al., 2010; Souli et al., 2008; Xavier et al., 2010) . To our knowledge, this work represents the first comprehensive assessment in Brazil of bacteraemia stemming from antimicrobialresistant P. aeruginosa, inappropriate therapy and death in a tertiary-care population.
It is often assumed that bacteraemia caused by antimicrobial-resistant P. aeruginosa results in higher rates of mortality due to the negative effect of the delay of the administration of an appropriate antibiotic therapy as well as the administration of an inactive antimicrobial (Kang et al., 2003 (Kang et al., , 2005 Lodise et al., 2007) . From our cohort of 120 patients with P. aeruginosa bacteraemia, 57 had an MDR profile and 31 had an XDR profile, and the presence of these isolates was significantly associated with inappropriate antimicrobial therapy, which was an independent predictor of death. The chances of an empirical therapy occurs inappropriately in patients hospitalized in tertiary care may be even greater, due to exposure to countless different risk factors to occurrence of infection by resistant strains (Joo et al., 2011; Peña et al., 2012) . In our study, the presence of pneumonia and hospitalization in the ICU were independent risk factors for developing bacteraemia due to MDR or XDR P. aeruginosa. Several risk factors for antimicrobial resistance were statistically significant; however, after adjusting the variables, the independent risk factors identified were, mainly, prior antimicrobial therapy and length of stay .30 days prior to infection. Zavascki et al. (2006) showed that MBL-producing P. aeruginosa increases the risk of inappropriate therapy, thus increasing the mortality. This aspect was not assessed in our study, but we detected a relatively high percentage (77.8 %; 7/9) of MBL genes amongst phenotypically positive isolates, of which 57 % (4/7) were bla SPM-1 and 43 % (3/7) were bla VIM -type. However, most of our carbapenem-resistant isolates (80.5 %; 29/36) were negative for MBL genes, suggesting the existence of other MBLs not tested and other drug resistance mechanisms, such as the upregulation of intrinsic cephalosporinase AmpC production, overexpression of efflux systems and outer membrane impermeability (porin loss) (Xavier et al., 2010) . These results revealed an important change in the epidemiology of carbapenem-resistant P. aeruginosa isolates between 2005 (Cezário et al., 2009) and 2011 in our hospital, revealing an increasing prevalence of the VIM-MBLproducing isolates in the final period of study.
Several retrospective works, including regional studies from Brazil, have evaluated the mortality of patients with P. aeruginosa bacteraemia, and some of these showed that the impact of antimicrobial resistance on patient outcomes might depend on the severity of underlying conditions, primary source of infection and inappropriate therapy (Kang et al., 2003 (Kang et al., , 2005 Furtado et al., 2009 ). Our study further confirmed the notion that patients who are infected with antimicrobialresistant P. aeruginosa isolates normally have worse treatment outcomes and this has been found to be a strong prognostic factor for mortality, even after adjusting for the severity of illness and the underlying condition (Joo et al., 2011) .
Previous studies also showed that P. aeruginosa isolated from patients who had been exposed to previous antimicrobial therapy prior to the development of bacteraemia had an increased risk of being resistant to different classes of antibiotics (Joo et al., 2011; Peña et al., 2012) . Unlike in other studies, the frequencies of ceftazidime (55 %) piperacillin/tazobactam (35 %) and fluoroquinolone resistance (44 %) were much higher in the current study, suggesting the existence of different resistance mechanisms. We also highlight the frequent use of cephalosporins and fluoroquinolones in our hospital. All isolates were susceptible to polymyxin B, which has resurfaced for the empirical treatment of P. aeruginosa infections due to the lack of new effective antibiotics, although reports of clinical P. aeruginosa isolates with reduced susceptibility to this antimicrobial class have been reported, including strains producing MBL (Franco et al., 2010; Laupland et al., 2005) .
In summary, our results indicate that a high incidence of MDR and XDR isolates exists amongst hospitalized patients with bacteraemia. In addition, our data suggest that antimicrobial resistance, especially cefepime-resistant isolates and MDR or XDR strains, adversely affect outcomes in patients with P. aeruginosa bacteraemia through inadequate therapy. Thus, the monitoring of resistant P. aeruginosa isolates and the knowledge of the factors associated with this resistance is important in order to prevent the emergence of pandrug resistance amongst clinical isolates of P. aeruginosa in our hospital.
